Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: A prospective cohort study

Only a subset of cervical precursor lesions progress to cervical cancer and because of the lack of the predictive markers, it cannot be ascertained which lesions will progress or not. To estimate the risk of disease progression associated with human papillomavirus (HPV) genotypes, we followed 570 Ja...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of cancer Vol. 128; no. 12; pp. 2898 - 2910
Main Authors Matsumoto, Koji, Oki, Akinori, Furuta, Reiko, Maeda, Hiroo, Yasugi, Toshiharu, Takatsuka, Naoyoshi, Mitsuhashi, Akira, Fujii, Takuma, Hirai, Yasuo, Iwasaka, Tsuyoshi, Yaegashi, Nobuo, Watanabe, Yoh, Nagai, Yutaka, Kitagawa, Tomoyuki, Yoshikawa, Hiroyuki
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 15.06.2011
Wiley-Blackwell
Subjects
Age
Alphapapillomavirus - genetics
Base Sequence
Biological and medical sciences
Cervical cancer
Cervical Intraepithelial Neoplasia - pathology
Cervical Intraepithelial Neoplasia - virology
Cervix
CIN
Disease Progression
DNA Primers
DNA, Viral - genetics
Female
Genotype
Genotypes
Genotyping
HPV
Human papillomavirus
Humans
Infection
Infectious diseases
LSIL
Medical sciences
Neoplasia
Prospective Studies
Risk assessment
Risk factors
Risk groups
Tumors
Viral diseases
Premalignant lesion
Genotype
CIN
LSIL
Papovaviridae
Precursor
Female genital diseases
HPV
Infection
Papillomavirus
Virus
Prospective
Human papillomavirus
Cancerology
Cohort study
Viral disease
Cervical intraepithelial neoplasia
Uterine cervix diseases
Online AccessGet full text
ISSN0020-7136
1097-0215
1097-0215
DOI10.1002/ijc.25630

Cover

Abstract Only a subset of cervical precursor lesions progress to cervical cancer and because of the lack of the predictive markers, it cannot be ascertained which lesions will progress or not. To estimate the risk of disease progression associated with human papillomavirus (HPV) genotypes, we followed 570 Japanese women with cytological LSIL (low‐grade squamous intraepithelial lesion) and histological CIN (cervical intraepithelial neoplasia) grade 1–2 lesions (479 CIN 1; 91 CIN 2) at 3 to 4 month intervals for a mean follow‐up period of 39.1 months. At entry, we detected HPV DNA in cervical samples by polymerase chain reaction‐based methodology. Over the period of follow‐up period, 46 lesions progressed to CIN 3 while 362 regressed to normal cytology. Women with multiple HPV infections were more likely to have persistent lesions (hazard ratio [HR] for regression, 0.65; 95% confidence interval [CI], 0.42–1.02; p = 0.07); however, multiple infections did not increase the risk of progression (HR for progression, 1.04; 95% CI, 0.37–2.94; p = 0.94). After adjusting for CIN grade and women's age, HRs for progression to CIN 3 (vs. women with low‐risk types or negative for HPV DNA) varied markedly by HPV genotype: type 16 (11.1, 95% CI: 1.39–88.3); 18 (14.1, 0.65–306); 31 (24.7, 2.51–243); 33 (20.3, 1.78–231); 35 (13.7, 0.75–251); 52 (11.6, 1.45–93.3); 58 (8.85, 1.01–77.6); other high‐risk types (4.04, 0.47–34.7). HPV 45 was not detected in our study subjects. The cumulative probability of CIN 3 within 5 years was 20.5% for HPV 16, 18, 31, 33, 35, 52 and 58; 6.0% for other high‐risk types; 1.7% for low‐risk types (p = 0.0001). In conclusion, type‐specific HPV testing for women with LSIL/CIN 1–2 lesions is useful for identifying populations at increased or decreased risk of disease progression.
AbstractList Only a subset of cervical precursor lesions progress to cervical cancer and because of the lack of the predictive markers, it cannot be ascertained which lesions will progress or not. To estimate the risk of disease progression associated with human papillomavirus (HPV) genotypes, we followed 570 Japanese women with cytological LSIL (low-grade squamous intraepithelial lesion) and histological CIN (cervical intraepithelial neoplasia) grade 1-2 lesions (479 CIN 1; 91 CIN 2) at 3 to 4 month intervals for a mean follow-up period of 39.1 months. At entry, we detected HPV DNA in cervical samples by polymerase chain reaction-based methodology. Over the period of follow-up period, 46 lesions progressed to CIN 3 while 362 regressed to normal cytology. Women with multiple HPV infections were more likely to have persistent lesions (hazard ratio [HR] for regression, 0.65; 95% confidence interval [CI], 0.42-1.02; p = 0.07); however, multiple infections did not increase the risk of progression (HR for progression, 1.04; 95% CI, 0.37-2.94; p = 0.94). After adjusting for CIN grade and women's age, HRs for progression to CIN 3 (vs. women with low-risk types or negative for HPV DNA) varied markedly by HPV genotype: type 16 (11.1, 95% CI: 1.39-88.3); 18 (14.1, 0.65-306); 31 (24.7, 2.51-243); 33 (20.3, 1.78-231); 35 (13.7, 0.75-251); 52 (11.6, 1.45-93.3); 58 (8.85, 1.01-77.6); other high-risk types (4.04, 0.47-34.7). HPV 45 was not detected in our study subjects. The cumulative probability of CIN 3 within 5 years was 20.5% for HPV 16, 18, 31, 33, 35, 52 and 58; 6.0% for other high-risk types; 1.7% for low-risk types (p = 0.0001). In conclusion, type-specific HPV testing for women with LSIL/CIN 1-2 lesions is useful for identifying populations at increased or decreased risk of disease progression.Only a subset of cervical precursor lesions progress to cervical cancer and because of the lack of the predictive markers, it cannot be ascertained which lesions will progress or not. To estimate the risk of disease progression associated with human papillomavirus (HPV) genotypes, we followed 570 Japanese women with cytological LSIL (low-grade squamous intraepithelial lesion) and histological CIN (cervical intraepithelial neoplasia) grade 1-2 lesions (479 CIN 1; 91 CIN 2) at 3 to 4 month intervals for a mean follow-up period of 39.1 months. At entry, we detected HPV DNA in cervical samples by polymerase chain reaction-based methodology. Over the period of follow-up period, 46 lesions progressed to CIN 3 while 362 regressed to normal cytology. Women with multiple HPV infections were more likely to have persistent lesions (hazard ratio [HR] for regression, 0.65; 95% confidence interval [CI], 0.42-1.02; p = 0.07); however, multiple infections did not increase the risk of progression (HR for progression, 1.04; 95% CI, 0.37-2.94; p = 0.94). After adjusting for CIN grade and women's age, HRs for progression to CIN 3 (vs. women with low-risk types or negative for HPV DNA) varied markedly by HPV genotype: type 16 (11.1, 95% CI: 1.39-88.3); 18 (14.1, 0.65-306); 31 (24.7, 2.51-243); 33 (20.3, 1.78-231); 35 (13.7, 0.75-251); 52 (11.6, 1.45-93.3); 58 (8.85, 1.01-77.6); other high-risk types (4.04, 0.47-34.7). HPV 45 was not detected in our study subjects. The cumulative probability of CIN 3 within 5 years was 20.5% for HPV 16, 18, 31, 33, 35, 52 and 58; 6.0% for other high-risk types; 1.7% for low-risk types (p = 0.0001). In conclusion, type-specific HPV testing for women with LSIL/CIN 1-2 lesions is useful for identifying populations at increased or decreased risk of disease progression.
Only a subset of cervical precursor lesions progress to cervical cancer and because of the lack of the predictive markers, it cannot be ascertained which lesions will progress or not. To estimate the risk of disease progression associated with human papillomavirus (HPV) genotypes, we followed 570 Japanese women with cytological LSIL (low‐grade squamous intraepithelial lesion) and histological CIN (cervical intraepithelial neoplasia) grade 1–2 lesions (479 CIN 1; 91 CIN 2) at 3 to 4 month intervals for a mean follow‐up period of 39.1 months. At entry, we detected HPV DNA in cervical samples by polymerase chain reaction‐based methodology. Over the period of follow‐up period, 46 lesions progressed to CIN 3 while 362 regressed to normal cytology. Women with multiple HPV infections were more likely to have persistent lesions (hazard ratio [HR] for regression, 0.65; 95% confidence interval [CI], 0.42–1.02; p = 0.07); however, multiple infections did not increase the risk of progression (HR for progression, 1.04; 95% CI, 0.37–2.94; p = 0.94). After adjusting for CIN grade and women's age, HRs for progression to CIN 3 (vs. women with low‐risk types or negative for HPV DNA) varied markedly by HPV genotype: type 16 (11.1, 95% CI: 1.39–88.3); 18 (14.1, 0.65–306); 31 (24.7, 2.51–243); 33 (20.3, 1.78–231); 35 (13.7, 0.75–251); 52 (11.6, 1.45–93.3); 58 (8.85, 1.01–77.6); other high‐risk types (4.04, 0.47–34.7). HPV 45 was not detected in our study subjects. The cumulative probability of CIN 3 within 5 years was 20.5% for HPV 16, 18, 31, 33, 35, 52 and 58; 6.0% for other high‐risk types; 1.7% for low‐risk types (p = 0.0001). In conclusion, type‐specific HPV testing for women with LSIL/CIN 1–2 lesions is useful for identifying populations at increased or decreased risk of disease progression.
Only a subset of cervical precursor lesions progress to cervical cancer and because of the lack of the predictive markers, it cannot be ascertained which lesions will progress or not. To estimate the risk of disease progression associated with human papillomavirus (HPV) genotypes, we followed 570 Japanese women with cytological LSIL (low-grade squamous intraepithelial lesion) and histological CIN (cervical intraepithelial neoplasia) grade 1-2 lesions (479 CIN 1; 91 CIN 2) at 3 to 4 month intervals for a mean follow-up period of 39.1 months. At entry, we detected HPV DNA in cervical samples by polymerase chain reaction-based methodology. Over the period of follow-up period, 46 lesions progressed to CIN 3 while 362 regressed to normal cytology. Women with multiple HPV infections were more likely to have persistent lesions (hazard ratio [HR] for regression, 0.65; 95% confidence interval [CI], 0.42-1.02; p = 0.07); however, multiple infections did not increase the risk of progression (HR for progression, 1.04; 95% CI, 0.37-2.94; p = 0.94). After adjusting for CIN grade and women's age, HRs for progression to CIN 3 (vs. women with low-risk types or negative for HPV DNA) varied markedly by HPV genotype: type 16 (11.1, 95% CI: 1.39-88.3); 18 (14.,0.65-306); 31 (24.7, 2.51-243); 33 (20.3, 1.78-231); 35 (13.,0.75-251); 52 (11.6, 1.45-93.3); 58 (8.85, 1.01-77.6); other high-risk types (4.0,0.47-34.7). HPV 45 was not detected in our study subjects. The cumulative probability of CIN 3 within 5 years was 20.5% for HPV 16, 18, 31, 33, 35, 52 and 58; 6.0% for other high-risk types; 1.7% for low-risk types (p = 0.0001). In conclusion, type-specific HPV testing for women with LSIL/CIN 1-2 lesions is useful for identifying populations at increased or decreased risk of disease progression.
Only a subset of cervical precursor lesions progress to cervical cancer and because of the lack of the predictive markers, it cannot be ascertained which lesions will progress or not. To estimate the risk of disease progression associated with human papillomavirus (HPV) genotypes, we followed 570 Japanese women with cytological LSIL (low‐grade squamous intraepithelial lesion) and histological CIN (cervical intraepithelial neoplasia) grade 1–2 lesions (479 CIN 1; 91 CIN 2) at 3 to 4 month intervals for a mean follow‐up period of 39.1 months. At entry, we detected HPV DNA in cervical samples by polymerase chain reaction‐based methodology. Over the period of follow‐up period, 46 lesions progressed to CIN 3 while 362 regressed to normal cytology. Women with multiple HPV infections were more likely to have persistent lesions (hazard ratio [HR] for regression, 0.65; 95% confidence interval [CI], 0.42–1.02; p = 0.07); however, multiple infections did not increase the risk of progression (HR for progression, 1.04; 95% CI, 0.37–2.94; p = 0.94). After adjusting for CIN grade and women's age, HRs for progression to CIN 3 ( vs. women with low‐risk types or negative for HPV DNA) varied markedly by HPV genotype: type 16 (11.1, 95% CI: 1.39–88.3); 18 (14.1, 0.65–306); 31 (24.7, 2.51–243); 33 (20.3, 1.78–231); 35 (13.7, 0.75–251); 52 (11.6, 1.45–93.3); 58 (8.85, 1.01–77.6); other high‐risk types (4.04, 0.47–34.7). HPV 45 was not detected in our study subjects. The cumulative probability of CIN 3 within 5 years was 20.5% for HPV 16, 18, 31, 33, 35, 52 and 58; 6.0% for other high‐risk types; 1.7% for low‐risk types ( p = 0.0001). In conclusion, type‐specific HPV testing for women with LSIL/CIN 1–2 lesions is useful for identifying populations at increased or decreased risk of disease progression.
Author Oki, Akinori
Kitagawa, Tomoyuki
Iwasaka, Tsuyoshi
Yoshikawa, Hiroyuki
Furuta, Reiko
Takatsuka, Naoyoshi
Nagai, Yutaka
Watanabe, Yoh
Mitsuhashi, Akira
Yasugi, Toshiharu
Matsumoto, Koji
Fujii, Takuma
Hirai, Yasuo
Yaegashi, Nobuo
Maeda, Hiroo
Author_xml – sequence: 1
  givenname: Koji
  surname: Matsumoto
  fullname: Matsumoto, Koji
  email: matsumok@mui.biglobe.ne.jp
– sequence: 2
  givenname: Akinori
  surname: Oki
  fullname: Oki, Akinori
– sequence: 3
  givenname: Reiko
  surname: Furuta
  fullname: Furuta, Reiko
– sequence: 4
  givenname: Hiroo
  surname: Maeda
  fullname: Maeda, Hiroo
– sequence: 5
  givenname: Toshiharu
  surname: Yasugi
  fullname: Yasugi, Toshiharu
– sequence: 6
  givenname: Naoyoshi
  surname: Takatsuka
  fullname: Takatsuka, Naoyoshi
– sequence: 7
  givenname: Akira
  surname: Mitsuhashi
  fullname: Mitsuhashi, Akira
– sequence: 8
  givenname: Takuma
  surname: Fujii
  fullname: Fujii, Takuma
– sequence: 9
  givenname: Yasuo
  surname: Hirai
  fullname: Hirai, Yasuo
– sequence: 10
  givenname: Tsuyoshi
  surname: Iwasaka
  fullname: Iwasaka, Tsuyoshi
– sequence: 11
  givenname: Nobuo
  surname: Yaegashi
  fullname: Yaegashi, Nobuo
– sequence: 12
  givenname: Yoh
  surname: Watanabe
  fullname: Watanabe, Yoh
– sequence: 13
  givenname: Yutaka
  surname: Nagai
  fullname: Nagai, Yutaka
– sequence: 14
  givenname: Tomoyuki
  surname: Kitagawa
  fullname: Kitagawa, Tomoyuki
– sequence: 15
  givenname: Hiroyuki
  surname: Yoshikawa
  fullname: Yoshikawa, Hiroyuki
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24177065$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/20734388$$D View this record in MEDLINE/PubMed
BookMark eNp9kcFu1DAURS3Uik4LC34AeYOARdrnceI43VUjWooqwQLWkeO8zLhy4mA7U-Xv8XQGKlWiC8uS33lH1r2n5GhwAxLyjsE5A1hemHt9viwEh1dkwaAqM1iy4ogs0gyyknFxQk5DuAdgrID8NTlZQslzLuWCPPzw2BodzbCmcYN09G7tMQTjBuo6qtFvjVY2vaOefHCeWtwNA21mupl6NdBRjcZa16ut8VOgaxxcnMckvKRXO18YMfm3SLXbOB9piFM7vyHHnbIB3x7uM_Lr-svP1dfs7vvN7erqLtO5lJBVrFM5aFY0PJ1CiU53JUjAquENSCmw4E3LRFdorZnMEWXbtBy0bFDksuVn5OPemz7ye8IQ694EjdaqAd0Uail4KapkTOSnF0mWwpQ555VI6PsDOjU9tvXoTa_8XP-NNQEfDoAKKb3Oq0Gb8MTlrCxBFIn7vOd0iil47P4hDOpdtXWqtn6sNrEXz1htooqpi-iVsS9tPBiL8__V9e231X7jD0xrtoE
CODEN IJCNAW
CitedBy_id crossref_primary_10_1111_jog_14931
crossref_primary_10_1002_14651858_CD013807
crossref_primary_10_5795_jjscc_56_276
crossref_primary_10_1155_2020_4542320
crossref_primary_10_1111_jog_12196
crossref_primary_10_1155_2020_5058928
crossref_primary_10_1007_s10552_014_0471_6
crossref_primary_10_25259_Cytojournal_7_2024
crossref_primary_10_1002_ijc_27680
crossref_primary_10_3390_vaccines9040329
crossref_primary_10_1097_LGT_0000000000000596
crossref_primary_10_1186_s13027_020_00332_5
crossref_primary_10_2185_jrm_2020_038
crossref_primary_10_1016_j_gocm_2023_01_001
crossref_primary_10_1097_OLQ_0000000000001327
crossref_primary_10_1007_s10147_011_0322_3
crossref_primary_10_1016_j_pdpdt_2020_102172
crossref_primary_10_1186_s12985_016_0594_3
crossref_primary_10_1038_s41598_022_19722_3
crossref_primary_10_1002_cncy_21549
crossref_primary_10_3390_diagnostics10121013
crossref_primary_10_1111_jog_15995
crossref_primary_10_1016_j_arcmed_2022_11_009
crossref_primary_10_1111_jog_15997
crossref_primary_10_1002_ijc_30238
crossref_primary_10_1186_s12985_023_02125_9
crossref_primary_10_6004_jnccn_2022_7032
crossref_primary_10_1159_000501118
crossref_primary_10_1002_jmv_25775
crossref_primary_10_3192_jsirib_35_9
crossref_primary_10_1007_s10147_015_0789_4
crossref_primary_10_3390_v9040085
crossref_primary_10_1016_j_jviromet_2012_10_014
crossref_primary_10_1158_1055_9965_EPI_22_0054
crossref_primary_10_1002_jmv_22148
crossref_primary_10_1016_j_pvr_2018_10_005
crossref_primary_10_1136_bmjopen_2022_063622
crossref_primary_10_2185_jjrm_63_87
crossref_primary_10_37349_eds_2024_00063
crossref_primary_10_1002_ijc_29374
crossref_primary_10_1007_s10147_012_0486_5
crossref_primary_10_1007_s10147_014_0688_0
crossref_primary_10_1002_cam4_4470
crossref_primary_10_3802_jgo_2019_30_e52
crossref_primary_10_4103_JOC_JOC_19_19
crossref_primary_10_1002_jmv_28777
crossref_primary_10_1016_j_pdpdt_2020_102004
crossref_primary_10_1186_s12864_024_10411_1
crossref_primary_10_1038_jhg_2014_9
crossref_primary_10_3109_13697137_2015_1005592
crossref_primary_10_1093_jjco_hyad121
crossref_primary_10_7759_cureus_80201
crossref_primary_10_1002_ijc_27485
crossref_primary_10_1016_j_ygyno_2019_12_027
crossref_primary_10_1016_j_vaccine_2022_07_052
crossref_primary_10_1007_s40121_024_00952_z
crossref_primary_10_3390_cancers15153863
crossref_primary_10_1016_j_jare_2024_09_009
crossref_primary_10_1016_j_tjog_2023_10_002
crossref_primary_10_1097_QAI_0000000000000428
crossref_primary_10_1016_j_gofs_2024_08_001
crossref_primary_10_1155_2020_6878761
crossref_primary_10_25083_rbl_24_1_75_81
crossref_primary_10_1111_jog_12202
crossref_primary_10_1002_ijc_31633
crossref_primary_10_1093_jjco_hyz095
crossref_primary_10_1586_14737159_2015_1012068
crossref_primary_10_1002_jmv_26888
crossref_primary_10_1016_j_ijgo_2015_12_005
crossref_primary_10_1002_jmv_23258
crossref_primary_10_3390_cancers12020270
crossref_primary_10_1111_jog_16082
crossref_primary_10_2185_jjrm_63_29
crossref_primary_10_3802_jgo_2013_24_3_215
crossref_primary_10_1097_PGP_0000000000000228
crossref_primary_10_5795_jjscc_52_323
crossref_primary_10_1097_LGT_0000000000000604
crossref_primary_10_1016_S1470_2045_22_00291_1
crossref_primary_10_3802_jgo_2023_34_e2
crossref_primary_10_1093_jjco_hyz001
crossref_primary_10_1016_j_ejogrb_2013_07_012
crossref_primary_10_5795_jjscc_58_103
crossref_primary_10_1016_j_vaccine_2012_05_089
crossref_primary_10_1093_jjco_hyu112
crossref_primary_10_5306_wjco_v5_i5_931
crossref_primary_10_1007_s10552_023_01677_z
crossref_primary_10_1097_LGT_0000000000000573
crossref_primary_10_1038_s41598_019_55014_z
crossref_primary_10_18632_oncotarget_26627
crossref_primary_10_1111_jog_12068
crossref_primary_10_1007_s10147_023_02337_7
crossref_primary_10_1111_cas_14445
crossref_primary_10_1007_s10147_011_0280_9
crossref_primary_10_1097_01_PGO_0000406136_53050_5c
crossref_primary_10_18632_oncotarget_24169
crossref_primary_10_1309_AJCP53KMHNRDICBL
crossref_primary_10_1016_j_jcv_2013_06_026
crossref_primary_10_3802_jgo_2023_34_e14
crossref_primary_10_4264_numa_73_31
crossref_primary_10_1111_j_1447_0756_2012_01977_x
Cites_doi 10.1097/AOG.0b013e31818f5008
10.1111/j.1349-7006.1991.tb01882.x
10.1093/jnci/djg037
10.1001/jama.285.11.1500
10.1111/j.1447-0756.1996.tb00927.x
10.1002/ijc.22195
10.1097/pgp.0b013e31805152ab
10.1111/j.1525-1438.2007.00959.x
10.1093/jnci/95.1.46
10.1093/jnci/dji187
10.1016/j.ajog.2007.07.050
10.1016/S0166-0934(00)00194-4
10.1056/NEJMoa021641
10.1006/gyno.2000.6116
10.1016/j.ajog.2007.07.049
10.1038/sj.bjc.6601024
10.1002/ijc.20244
10.1128/JCM.00620-08
10.1038/nrc798
10.1128/JCM.01667-07
10.3322/canjclin.55.2.74
10.1016/j.ajog.2004.02.065
10.1097/01.AOG.0000220505.18525.85
10.1158/1055-9965.EPI-06-0129
10.1016/S0140-6736(04)17354-6
10.1016/S0029-7844(98)00245-2
10.1086/507909
10.1086/428850
10.1093/jnci/91.3.252
10.1016/S0140-6736(98)12490-X
10.1001/jama.298.7.743
10.1097/00004347-199304000-00018
10.1016/S0140-6736(07)61416-0
10.1158/0008-5472.CAN-06-1057
10.1038/sj.bjc.6600688
10.1158/1055-9965.EPI-04-0812
ContentType Journal Article
Copyright Copyright © 2010 UICC
2015 INIST-CNRS
Copyright © 2010 UICC.
Copyright_xml – notice: Copyright © 2010 UICC
– notice: 2015 INIST-CNRS
– notice: Copyright © 2010 UICC.
CorporateAuthor for Japan HPV And Cervical Cancer (JHACC) Study Group
Japan HPV And Cervical Cancer Study Group
CorporateAuthor_xml – name: for Japan HPV And Cervical Cancer (JHACC) Study Group
– name: Japan HPV And Cervical Cancer Study Group
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7U9
H94
7X8
DOI 10.1002/ijc.25630
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
Virology and AIDS Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

AIDS and Cancer Research Abstracts
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-0215
EndPage 2910
ExternalDocumentID 20734388
24177065
10_1002_ijc_25630
IJC25630
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: The Ministry of Education, Science, Sports and Culture of Japan
  funderid: 12218102
GroupedDBID ---
-~X
.3N
.GA
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABIJN
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEFGJ
AEGXH
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGXDD
AGYGG
AHBTC
AHMBA
AIACR
AIAGR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EX3
F00
F01
F04
F5P
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HZ~
IH2
IX1
J0M
JPC
KBYEO
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RX1
RYL
SUPJJ
TEORI
UB1
UDS
V2E
V8K
V9Y
W2D
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIJ
WIK
WJL
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
XG1
XPP
XV2
ZZTAW
~IA
~WT
AAHHS
AAYXX
ACCFJ
ADZOD
AEEZP
AEQDE
AIWBW
AJBDE
CITATION
.55
.GJ
3O-
53G
8WZ
A6W
AANHP
ABEFU
ABEML
ACBWZ
ACRPL
ACSCC
ACYXJ
ADNMO
AGHNM
AGQPQ
AHEFC
AI.
ASPBG
AVWKF
AZFZN
BDRZF
EMOBN
FEDTE
GLUZI
HVGLF
IQODW
M6P
PALCI
SAMSI
VH1
X7M
Y6R
ZGI
ZXP
24P
AEUQT
AFPWT
CGR
CUY
CVF
ECM
EIF
NPM
RWI
WIN
WRC
WUP
WWO
7U9
H94
7X8
ID FETCH-LOGICAL-c4880-91fa40c15b315b5a6fcf7080e9b3b0886e53bd16f5ccc184ee8dbd30c8be648d3
IEDL.DBID DR2
ISSN 0020-7136
1097-0215
IngestDate Fri Jul 11 11:31:48 EDT 2025
Thu Jul 10 23:51:16 EDT 2025
Wed Feb 19 01:57:01 EST 2025
Mon Jul 21 09:13:22 EDT 2025
Thu Apr 24 23:07:12 EDT 2025
Tue Jul 01 02:27:34 EDT 2025
Wed Aug 20 07:24:40 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Premalignant lesion
Genotype
CIN
LSIL
Papovaviridae
Precursor
Female genital diseases
HPV
Infection
Papillomavirus
Virus
Prospective
Human papillomavirus
Cancerology
Cohort study
Viral disease
Cervical intraepithelial neoplasia
Uterine cervix diseases
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
CC BY 4.0
Copyright © 2010 UICC.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4880-91fa40c15b315b5a6fcf7080e9b3b0886e53bd16f5ccc184ee8dbd30c8be648d3
Notes Tel.: +(81)‐29‐853‐3073, Fax: +(81)‐29‐853‐3072
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.25630
PMID 20734388
PQID 1020843396
PQPubID 23462
PageCount 13
ParticipantIDs proquest_miscellaneous_863769080
proquest_miscellaneous_1020843396
pubmed_primary_20734388
pascalfrancis_primary_24177065
crossref_primary_10_1002_ijc_25630
crossref_citationtrail_10_1002_ijc_25630
wiley_primary_10_1002_ijc_25630_IJC25630
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 15 June 2011
PublicationDateYYYYMMDD 2011-06-15
PublicationDate_xml – month: 06
  year: 2011
  text: 15 June 2011
  day: 15
PublicationDecade 2010
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: Hoboken, NJ
– name: United States
PublicationTitle International journal of cancer
PublicationTitleAlternate Int J Cancer
PublicationYear 2011
Publisher Wiley Subscription Services, Inc., A Wiley Company
Wiley-Blackwell
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
– name: Wiley-Blackwell
References 2005; 191
2004; 364
2006; 119
2001; 285
2008; 18
2000; 88
2006; 15
2002; 2
1991; 82
2009; 113
2006; 194
2003; 95
2001; 81
2004; 111
1993; 12
1976; 36
2006; 108
2003; 348
2007; 370
2004; 191
2006; 66
2007; 298
2007; 197
2005; 97
2008; 46
1998; 92
1999; 354
1999; 91
2005; 55
2003; 88
2007; 26
2003; 89
2005; 14
1996; 22
e_1_2_6_31_2
e_1_2_6_30_2
e_1_2_6_18_2
e_1_2_6_19_2
e_1_2_6_12_2
e_1_2_6_35_2
e_1_2_6_13_2
e_1_2_6_34_2
e_1_2_6_10_2
e_1_2_6_33_2
e_1_2_6_11_2
e_1_2_6_32_2
e_1_2_6_16_2
e_1_2_6_39_2
e_1_2_6_17_2
e_1_2_6_38_2
e_1_2_6_14_2
e_1_2_6_37_2
e_1_2_6_15_2
e_1_2_6_20_2
e_1_2_6_8_2
e_1_2_6_7_2
e_1_2_6_9_2
e_1_2_6_29_2
e_1_2_6_4_2
e_1_2_6_3_2
e_1_2_6_6_2
e_1_2_6_5_2
e_1_2_6_24_2
e_1_2_6_23_2
e_1_2_6_2_2
e_1_2_6_22_2
e_1_2_6_21_2
e_1_2_6_28_2
e_1_2_6_27_2
e_1_2_6_26_2
Youkeles L (e_1_2_6_36_2) 1976; 36
e_1_2_6_25_2
References_xml – volume: 89
  start-page: 101
  year: 2003
  end-page: 5
  article-title: Comparison of HPV type distribution in high‐grade cervical lesions and cervical cancer: a meta‐analysis
  publication-title: Br J Cancer
– volume: 95
  start-page: 1336
  year: 2003
  end-page: 43
  article-title: Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia
  publication-title: J Natl Cancer Inst
– volume: 111
  start-page: 278
  year: 2004
  end-page: 85
  article-title: Against which human papillomavirus types shall we vaccinate and screen? The international perspective
  publication-title: Int J Cancer
– volume: 14
  start-page: 1157
  year: 2005
  end-page: 64
  article-title: Human papillomavirus genotype distribution in low‐grade cervical lesions: comparison by geographic region and with cervical cancer
  publication-title: Cancer Epidemiol Biomarkers Prev
– volume: 95
  start-page: 46
  year: 2003
  end-page: 52
  article-title: Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10‐year cohort analysis
  publication-title: J Natl Cancer Inst
– volume: 18
  start-page: 71
  year: 2008
  end-page: 9
  article-title: ACCPAB members. Human papillomavirus type distribution in women from Asia: a meta‐analysis
  publication-title: Int J Gynecol Cancer
– volume: 348
  start-page: 518
  year: 2003
  end-page: 27
  article-title: International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer
  publication-title: N Engl J Med
– volume: 354
  start-page: 20
  year: 1999
  end-page: 5
  article-title: Relation of human papillomavirus status to cervical lesions and consequences for cervical‐cancer screening: a prospective study
  publication-title: Lancet
– volume: 298
  start-page: 743
  year: 2007
  end-page: 53
  article-title: Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial
  publication-title: JAMA
– volume: 15
  start-page: 1274
  year: 2006
  end-page: 80
  article-title: Human papillomavirus infections with multiple types and risk of cervical neoplasia
  publication-title: Cancer Epidemiol Biomarkers Prev
– volume: 36
  start-page: 2080
  year: 1976
  end-page: 4
  article-title: Evaluation of papanicolaou smear and effect of sample biopsy in follow‐up of cervical dysplasia
  publication-title: Cancer Res
– volume: 191
  start-page: 1796
  year: 2005
  end-page: 1807
  article-title: Epidemiologic profile of type‐specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica
  publication-title: J Infect Dis
– volume: 55
  start-page: 74
  year: 2005
  end-page: 108
  article-title: Global cancer statistics, 2002
  publication-title: CA Cancer J Clin
– volume: 370
  start-page: 890
  year: 2007
  end-page: 907
  article-title: Human papillomavirus and cervical cancer
  publication-title: Lancet
– volume: 197
  start-page: 356.e1
  year: 2007
  end-page: 6
  article-title: Risk assessment to guide the prevention of cervical cancer
  publication-title: Am J Obstet Gynecol
– volume: 88
  start-page: 125
  year: 2000
  end-page: 34
  article-title: Comparison of five different polymerase chain reaction methods for detection of human papillomavirus in cervical cell specimens
  publication-title: J Virol Methods
– volume: 22
  start-page: 1
  year: 1996
  end-page: 8
  article-title: Association of multiple human papillomavirus types with vulvar neoplasias
  publication-title: J Obstet Gynaecol Res
– volume: 194
  start-page: 1291
  year: 2006
  end-page: 9
  article-title: Atypical Squamous Cells of Undetermined Significance /Low‐Grade Squamous Intraepithelial Lesions Triage Study Group. Human papillomavirus genotypes and the cumulative 2‐year risk of cervical precancer
  publication-title: J Infect Dis
– volume: 81
  start-page: 47
  year: 2001
  end-page: 52
  article-title: Detection of human papillomaviruses in cervical neoplasias using multiple sets of generic polymerase chain reaction primers
  publication-title: Gynecol Oncol
– volume: 92
  start-page: 727
  year: 1998
  end-page: 35
  article-title: Natural history of cervical squamous intraepithelial lesions: a meta‐analysis
  publication-title: Obstet Gynecol
– volume: 88
  start-page: 63
  year: 2003
  end-page: 73
  article-title: Human papillomavirus types in invasive cervical cancer worldwide: a meta‐analysis
  publication-title: Br J Cancer
– volume: 82
  start-page: 524
  year: 1991
  end-page: 31
  article-title: Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers
  publication-title: Jpn J Cancer Res
– volume: 26
  start-page: 441
  year: 2007
  end-page: 6
  article-title: CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population‐based cervical samples
  publication-title: Int J Gynecol Pathol
– volume: 197
  start-page: 340
  year: 2007
  end-page: 5
  article-title: 2006 American Society for Colposcopy and Cervical Pathology‐sponsored Consensus Conference. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ
  publication-title: Am J Obstet Gynecol
– volume: 97
  start-page: 1072
  year: 2005
  end-page: 9
  article-title: The elevated 10‐year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type‐specific HPV testing in clinical practice
  publication-title: J Natl Cancer Inst
– volume: 2
  start-page: 342
  year: 2002
  end-page: 50
  article-title: Papillomaviruses and cancer: from basic studies to clinical application
  publication-title: Nat Rev Cancer
– volume: 191
  start-page: 430
  year: 2004
  end-page: 4
  article-title: Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse
  publication-title: Am J Obstet Gynecol
– volume: 91
  start-page: 252
  year: 1999
  end-page: 8
  article-title: Natural history of dysplasia of the uterine cervix
  publication-title: J Natl Cancer Inst
– volume: 66
  start-page: 10630
  year: 2006
  end-page: 6
  article-title: The absolute risk of cervical abnormalities in high‐risk human papillomavirus‐positive, cytologically normal women over a 10‐year period
  publication-title: Cancer Res
– volume: 108
  start-page: 264
  year: 2006
  end-page: 72
  article-title: Number of cervical biopsies and sensitivity of colposcopy
  publication-title: Obstet Gynecol
– volume: 12
  start-page: 186
  year: 1993
  end-page: 92
  article-title: Natural history of cervical intraepithelial neoplasia: a critical review
  publication-title: Int J Gynecol Pathol
– volume: 119
  start-page: 2713
  year: 2006
  end-page: 5
  article-title: Do we need a different strategy for HPV screening and vaccination in East Asia?
  publication-title: Int J Cancer
– volume: 46
  start-page: 109
  year: 2008
  end-page: 17
  article-title: Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low‐grade squamous intraepithelial lesion triage study
  publication-title: J Clin Microbiol
– volume: 46
  start-page: 3437
  year: 2008
  end-page: 45
  article-title: CVT Group. Comparison of two PCR‐based human papillomavirus genotyping methods
  publication-title: J Clin Microbiol
– volume: 285
  start-page: 1500
  year: 2001
  end-page: 5
  article-title: Atypical Squamous Cells of Undetermined Significance‐Low‐grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS‐LSIL Triage Study
  publication-title: JAMA
– volume: 113
  start-page: 18
  year: 2009
  end-page: 25
  article-title: Evidence for frequent regression of cervical intraepithelial neoplasia‐grade 2
  publication-title: Obstet Gynecol
– volume: 364
  start-page: 1678
  year: 2004
  end-page: 83
  article-title: Regression of low‐grade squamous intra‐epithelial lesions in young women
  publication-title: Lancet
– ident: e_1_2_6_7_2
  doi: 10.1097/AOG.0b013e31818f5008
– ident: e_1_2_6_19_2
  doi: 10.1111/j.1349-7006.1991.tb01882.x
– ident: e_1_2_6_37_2
  doi: 10.1093/jnci/djg037
– ident: e_1_2_6_25_2
  doi: 10.1001/jama.285.11.1500
– ident: e_1_2_6_22_2
  doi: 10.1111/j.1447-0756.1996.tb00927.x
– ident: e_1_2_6_28_2
  doi: 10.1002/ijc.22195
– ident: e_1_2_6_26_2
  doi: 10.1097/pgp.0b013e31805152ab
– ident: e_1_2_6_29_2
  doi: 10.1111/j.1525-1438.2007.00959.x
– ident: e_1_2_6_15_2
  doi: 10.1093/jnci/95.1.46
– ident: e_1_2_6_17_2
  doi: 10.1093/jnci/dji187
– ident: e_1_2_6_9_2
  doi: 10.1016/j.ajog.2007.07.050
– ident: e_1_2_6_20_2
  doi: 10.1016/S0166-0934(00)00194-4
– ident: e_1_2_6_12_2
  doi: 10.1056/NEJMoa021641
– ident: e_1_2_6_21_2
  doi: 10.1006/gyno.2000.6116
– ident: e_1_2_6_8_2
  doi: 10.1016/j.ajog.2007.07.049
– ident: e_1_2_6_13_2
  doi: 10.1038/sj.bjc.6601024
– ident: e_1_2_6_23_2
  doi: 10.1002/ijc.20244
– ident: e_1_2_6_34_2
  doi: 10.1128/JCM.00620-08
– ident: e_1_2_6_10_2
  doi: 10.1038/nrc798
– ident: e_1_2_6_33_2
  doi: 10.1128/JCM.01667-07
– ident: e_1_2_6_2_2
  doi: 10.3322/canjclin.55.2.74
– ident: e_1_2_6_38_2
  doi: 10.1016/j.ajog.2004.02.065
– ident: e_1_2_6_39_2
  doi: 10.1097/01.AOG.0000220505.18525.85
– ident: e_1_2_6_32_2
  doi: 10.1158/1055-9965.EPI-06-0129
– ident: e_1_2_6_35_2
  doi: 10.1016/S0140-6736(04)17354-6
– ident: e_1_2_6_5_2
  doi: 10.1016/S0029-7844(98)00245-2
– ident: e_1_2_6_18_2
  doi: 10.1086/507909
– ident: e_1_2_6_31_2
  doi: 10.1086/428850
– ident: e_1_2_6_6_2
  doi: 10.1093/jnci/91.3.252
– ident: e_1_2_6_27_2
  doi: 10.1016/S0140-6736(98)12490-X
– ident: e_1_2_6_3_2
  doi: 10.1001/jama.298.7.743
– volume: 36
  start-page: 2080
  year: 1976
  ident: e_1_2_6_36_2
  article-title: Evaluation of papanicolaou smear and effect of sample biopsy in follow‐up of cervical dysplasia
  publication-title: Cancer Res
– ident: e_1_2_6_4_2
  doi: 10.1097/00004347-199304000-00018
– ident: e_1_2_6_11_2
  doi: 10.1016/S0140-6736(07)61416-0
– ident: e_1_2_6_30_2
– ident: e_1_2_6_16_2
  doi: 10.1158/0008-5472.CAN-06-1057
– ident: e_1_2_6_24_2
  doi: 10.1038/sj.bjc.6600688
– ident: e_1_2_6_14_2
  doi: 10.1158/1055-9965.EPI-04-0812
SSID ssj0011504
Score 2.3609676
Snippet Only a subset of cervical precursor lesions progress to cervical cancer and because of the lack of the predictive markers, it cannot be ascertained which...
SourceID proquest
pubmed
pascalfrancis
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2898
SubjectTerms Age
Alphapapillomavirus - genetics
Base Sequence
Biological and medical sciences
Cervical cancer
Cervical Intraepithelial Neoplasia - pathology
Cervical Intraepithelial Neoplasia - virology
Cervix
CIN
Disease Progression
DNA Primers
DNA, Viral - genetics
Female
Genotype
Genotypes
Genotyping
HPV
Human papillomavirus
Humans
Infection
Infectious diseases
LSIL
Medical sciences
Neoplasia
Prospective Studies
Risk assessment
Risk factors
Risk groups
Tumors
Viral diseases
Title Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: A prospective cohort study
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.25630
https://www.ncbi.nlm.nih.gov/pubmed/20734388
https://www.proquest.com/docview/1020843396
https://www.proquest.com/docview/863769080
Volume 128
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEF9KH0QQrZ89q2UVH3zJdZNNNht9KsVSCxURC30Qwn4FTq-XkOSU-tc7s5uknLQgPgQCmWx2JzOzv_36DSFvnIu1S4yJDIDhKM1FERVW2YgrbqWVRaIsHk4--yROztPTi-xii7wfz8IEfohpwg09w8drdHClu4Nr0tDFdzNPkN0K4i_u1UJA9GWijkKgMzAwswgGYmJkFWLJwfTmRl90r1EdqKUK-SxuApyb-NV3QMcPyLex6mHfyY_5utdz8_svVsf_bNsOuT8AU3oYLOkh2XKrR-TO2bD0_pj8-tziPe6SpgAaqd_YFUg9aF1R42MOFNC0OIPf1S1dOnzYUX1FfSZA2qhmsVzWl-rnol13FOlh-ys8r_WOHmJ546lPill725566tsn5Pz4w9ejk2jI2hAZDAYQPSuVMhNnmsOVKVGZKgdc6grNNcQ04TKubSyqzBgD40vnpNWWMyO1E6m0_CnZXtUrt0uoYUUVM8VyBZ0oDJTAqpzAaWzNlMwLMSNvx_9XmoHSHDNrLMtAxpyUoMjSK3JGXk-iTeDxuElof8MIJkmAOTmuB8_Iq9EqSnBDXFtRK1evOygoYTLlHCtFb5GRAqJ5AaqYkWfBoq4_AJE25VJCi7xd3F7H8uPpkb95_u-ie-RumAoXUZy9INt9u3YvAUv1et87zR--rBzH
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7SFNpC6fuxfaRq6aEXb2zLluXSSwgNmzQbSkkgl2IkWYZtNrvG9rakv74z8iNsSaD0YDB4LEvyaPTNSPoG4L21gbahMZ5BMOxFiUi9NFe5xxXPZS7TUOV0OHl6JCYn0cFpfLoBn_qzMC0_xBBwo5Hh7DUNcApIb1-yhs5-mHFI9FY34CZl9HYO1beBPIqgTsfB7HvoiomeV8gPt4dX12aju6WqsWOKNqPFVZBzHcG6KWjvPnzvK9_uPDkbrxo9Nr__4nX839Y9gHsdNmU7rTI9hA27eAS3pt3q-2P49bWie9oozRA3Mre3q-X1YMuCGWd2sICyoiB-vazY3NLDmukL5pIBslKVs_l8ea5-zqpVzYghtrmgI1sf2Q6V1x_8ZJS4t2qYY799Aid7n493J16XuMEzZA_QgBYq8k0Qa45XrERhigShqU0112jWhI25zgNRxMYYdDGtlbnOuW-ktiKSOX8Km4vlwj4HZvy0CHzlJwrnUfSVULGsoEi29pVMUjGCD_0PzEzHak7JNeZZy8ccZtiRmevIEbwbRMuWyuMqoa01LRgkEekktCQ8gre9WmQ4Eml5RS3sclVjQaEvI86pUuwaGSnQoKfYFSN41qrU5QfQ2EZcSmyRU4zr65jtH-y6mxf_LvoGbk-Op4fZ4f7Rl5dwp42MCy-IX8FmU63sa4RWjd5yI-gPaf0g4g
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEF9qhSKI39Xzo67igy-5brLJZqNPpfVoqy1FLPRBCPsVuPa8hCSn1L_emc0l5aQF8SEQyGSzO5mZ_e3Xbwh551yoXWRMYAAMB3EqsiCzygZccSutzCJl8XDy0bHYP40Pz5KzNfKxPwvT8UMME27oGT5eo4NXtti-Ig2dnptxhOxWt8jtWDCJJr33deCOQqSzpGBmAYzERE8rxKLt4dWVzuhupRrQS9EltLgOca4CWN8DTe6T733du40nF-NFq8fm91-0jv_ZuAfk3hKZ0p3OlB6SNTd_RDaOlmvvj8mvkxrvcZs0BdRI_c6ujtWDlgU1PuhAAVWNU_hNWdOZw4cN1ZfUpwKklaqms1n5Q_2c1ouGIj9se4kHtj7QHSyvP_ZJMW1v3VLPffuEnE4-fdvdD5ZpGwKD0QDCZ6FiZsJEc7gSJQpTpABMXaa5hqAmXMK1DUWRGGNggOmctNpyZqR2IpaWb5L1eTl3zwg1LCtCpliqoBeFkRKYlRM4j62ZkmkmRuR9__9ys-Q0x9Qas7xjY45yUGTuFTkibwfRqiPyuE5oa8UIBknAOSkuCI_Im94qcvBDXFxRc1cuGigoYjLmHCtFb5CRAsJ5BqoYkaedRV19AEJtzKWEFnm7uLmO-cHhrr95_u-ir8nGyd4k_3Jw_PkFudNNi4sgTF6S9bZeuFeAq1q95f3nDxZCH5o
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predicting+the+progression+of+cervical+precursor+lesions+by+human+papillomavirus+genotyping%3A+a+prospective+cohort+study&rft.jtitle=International+journal+of+cancer&rft.au=Matsumoto%2C+Koji&rft.au=Oki%2C+Akinori&rft.au=Furuta%2C+Reiko&rft.au=Maeda%2C+Hiroo&rft.date=2011-06-15&rft.eissn=1097-0215&rft.volume=128&rft.issue=12&rft.spage=2898&rft_id=info:doi/10.1002%2Fijc.25630&rft_id=info%3Apmid%2F20734388&rft.externalDocID=20734388
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon